Announcements
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
Date of occurrence of the event: Nov 21, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
Department of Health (DOH) clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study in Hong Kong
Date of occurrence of the event: Nov 15, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
Investigational Device Exemption (IDE) for the development of OBI-888 was approved by the US Food and Drug Administration (FDA) for its use in OBI-888 Phase I cohort expansion phase
Date of occurrence of the event: Nov 12, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study in the United States
Date of occurrence of the event: Nov 02, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
OBI Pharma Australia Pty Ltd announces the clearance of Adogloxad Simolenin (OBI-822) for a Phase III clinical study in Australia
Date of occurrence of the event: Oct 29, 2018 Company name: OBI Pharma Australia Pty Ltd Relationship to the Company (please enter “head office” or “subsidiaries”): subsidiary Reciprocal shareholding ratios: …
OBI received notice from patent attorney’s office that product patent for OBI-822 named “Compound and Compositions of Carbohydrate Vaccine and Uses Thereof” has been approved by Taiwan Intellectual Property Office
Date of occurrence of the event: Oct 01, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
Taiwan FDA clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study
Date of occurrence of the event: Sept 28, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
Correction on previous announcement: “Clarification on the news article by Commercial Times” to “United Daily News”
Date of occurrence of the event: Sept 20, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
Clarification on the news article by Commercial Times
Date of occurrence of the event: Sept 20, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
Date of occurrence of the event: Sept 19, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …